Avel eCare Announces Acquisition of Amwell Psychiatric Care to Expand Telemedicine Services
SIOUX FALLS, SD / ACCESSWIRE / January 9, 2025 / Avel eCare, the nation's leading telemedicine provider of clinician-to-clinician services,...
Day: January 9, 2025
CliniOps Announces Strategic Partnership With Indegene to Accelerate Clinical Trials
Offers an end-to-end platform for patient recruitment, data management, Biostatistics and regulatory submission FREMONT, CALIFORNIA / ACCESSWIRE / January 9,...
Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco
LOS GATOS, CA / ACCESSWIRE / January 9, 2025 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company...
Nanomerics Reports Complete Dosing of the Last Volunteer in the OC134 SUNLIGHT Trial
LONDON, GB / ACCESSWIRE / January 9, 2025 / Nanomerics Ltd., a private speciality pharmaceutical company today announced that it...
AI/ML Innovations Inc. Welcomes Industry Veterans to Board of Directors
Mark Orsmond, a highly respected business professional in Canadian Healthcare, Appointed Executive ChairMichael Nemirow Joins as Director, Bringing Decades of...
BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco
Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciencesMeet BioLizard’s...
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025...
Inmagene Reports Positive Topline Results of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-Life, for the Treatment of Atopic Dermatitis
A 4-week treatment with IMG-007 resulted in a mean reduction in eczema area and severity index (EASI) of 77% and...
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology
Cannabix Technologies Inc. Cannabix Breath Collection Unit (“BCU”) with Breath Cartridge technology VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE)...
FYR Appoints Chris Howlett to its Board of Directors
Appointment adds business, market and partner development expertise to FYR board Addition highlights FYR’s evolution into partner of choice for...
Alkeus Pharmaceuticals Announces New Positive Interim TEASE-3 Study Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients
Two additional TEASE-3 participants who recently completed 24 months of therapy showed no disease progression, consistent with prior results. A...
Hydreight Technologies Provides Shareholder Update on 2024 Milestones and 2025 Vision
VANCOUVER, British Columbia and LAS VEGAS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV:...
Biosphere Launches UV Bioreactor to Transform Industrial Fermentation
Following $8.8m seed round, Biosphere aims to slash biomanufacturing’s capital costs by more than 50% OAKLAND, Calif., Jan. 09, 2025...
Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships
Company Making Additions to Executive Team and Advisory Board to Support Significant Commercial MomentumLONDON, Jan. 09, 2025 (GLOBE NEWSWIRE) --...
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE...
Amwell® divests virtual psychiatric care business to Avel eCare in all-cash transaction
Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives Company reiterates guidance for 2024 BOSTON,...
Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies,...
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company...
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health...
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment...